Research progress in the application of ivabradine in children with cardiovascular diseases
JIANG Lu
Department of Cardiology, Children's Hospital of Chongqing Medical University/National Key Clinical Specialty/Ministry of Education Key Laboratory of Child Development and Disorders/National Clinical Research Center for Child Health and Disorders/China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing 400014, China
Abstract Ivabradine, as a specific If current inhibitor, has been widely used in the treatment of chronic heart failure in adults due to its ability to reduce heart rate without affecting myocardial contractility and blood pressure. It has also shown good effects in various types of tachyarrhythmias. However, the application of ivabradine in pediatric cardiovascular diseases still faces many limitations. This article reviews the current research progress on the use of ivabradine in treating pediatric cardiovascular diseases both domestically and internationally, aiming to provide guidance for pediatric cardiologists. Citation:Chinese Journal of Contemporary Pediatrics, 2024, 26(7): 782-788
Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J]. J Card Fail, 2017, 23(8): 628-651. PMID: 28461259. DOI: 10.1016/j.cardfail.2017.04.014.
Swedberg K, Komajda M, B?hm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study[J]. Lancet, 2010, 376(9744): 875-885. PMID: 20801500. DOI: 10.1016/S0140-6736(10)61198-1.
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. J Am Coll Cardiol, 2022, 79(17): e263-e421. PMID: 35379503. DOI: 10.1016/j.jacc.2021.12.012.
Bonnet D, Berger F, Jokinen E, et al. Ivabradine in children with dilated cardiomyopathy and symptomatic chronic heart failure[J]. J Am Coll Cardiol, 2017, 70(10): 1262-1272. PMID: 28859790. DOI: 10.1016/j.jacc.2017.07.725.
Ahmed A, Pothineni NVK, Charate R, et al. Inappropriate sinus tachycardia: etiology, pathophysiology, and management: JACC review topic of the week[J]. J Am Coll Cardiol, 2022, 79(24): 2450-2462. PMID: 35710196. DOI: 10.1016/j.jacc.2022.04.019.
Ugan Atik S, Dedeo?lu R, Koka A, et al. Our experience in the diagnosis and treatment of postural orthostatic tachycardia syndrome, vasovagal syncope, and inappropriate sinus tachycardia in children[J]. Turk Kardiyol Dern Ars, 2017, 45(3): 227-234. PMID: 28429690. DOI: 10.5543/tkda.2017.36517.
Buchhorn R, Baumann C, Gündogdu S, et al. Diagnosis and management of an inappropriate sinus tachycardia in adolescence based upon a Holter ECG: a retrospective analysis of 479 patients[J]. PLoS One, 2020, 15(8): e0238139. PMID: 32845894. PMCID: PMC7449400. DOI: 10.1371/journal.pone.0238139.
Hou CR, Olshansky B, Cortez D, et al. Inappropriate sinus tachycardia: an examination of existing definitions[J]. Europace, 2022, 24(10): 1655-1664. PMID: 35851637. DOI: 10.1093/europace/euac057.
Shabtaie SA, Witt CM, Asirvatham SJ. Efficacy of medical and ablation therapy for inappropriate sinus tachycardia: a single-center experience[J]. J Cardiovasc Electrophysiol, 2021, 32(4): 1053-1061. PMID: 33566447. DOI: 10.1111/jce.14942.
Mathew ST, Po SS, Thadani U. Inappropriate sinus tachycardia-symptom and heart rate reduction with ivabradine: a pooled analysis of prospective studies[J]. Heart Rhythm, 2018, 15(2): 240-247. PMID: 29017929. DOI: 10.1016/j.hrthm.2017.10.004.
Martino A, Rebecchi M, Sette A, et al. Ivabradine versus bisoprolol in the treatment of inappropriate sinus tachycardia: a long-term follow-up study[J]. J Cardiovasc Med (Hagerstown), 2021, 22(11): 892-900. PMID: 34747925. DOI: 10.2459/JCM.0000000000001203.
Brugada J, Katritsis DG, Arbelo E, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardia. The Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2020, 41(5): 655-720. PMID: 31504425. DOI: 10.1093/eurheartj/ehz467.
Romeo E, Grimaldi N, Sarubbi B, et al. A pediatric case of cardiomyopathy induced by inappropriate sinus tachycardia: efficacy of ivabradine[J]. Pediatr Cardiol, 2011, 32(6): 842-845. PMID: 21479666. DOI: 10.1007/s00246-011-9964-1.
Taub PR, Zadourian A, Lo HC, et al. Randomized trial of ivabradine in patients with hyperadrenergic postural orthostatic tachycardia syndrome[J]. J Am Coll Cardiol, 2021, 77(7): 861-871. PMID: 33602468. DOI: 10.1016/j.jacc.2020.12.029.
Delle Donne G, Rosés Noguer F, Till J, et al. Ivabradine in postural orthostatic tachycardia syndrome: preliminary experience in children[J]. Am J Cardiovasc Drugs, 2018, 18(1): 59-63. PMID: 29027608. DOI: 10.1007/s40256-017-0248-x.
Towheed A, Nesheiwat Z, Mangi MA, et al. Ivabradine in children with postural orthostatic tachycardia syndrome: a retrospective study[J]. Cardiol Young, 2020, 30(7): 975-979. PMID: 32498748. DOI: 10.1017/S1047951120001341.
Bohora S, Lokhandwala Y, Parekh P, et al. Reversal of tachycardiomyopathy due to left atrial tachycardia by ivabradine[J]. J Cardiovasc Electrophysiol, 2011, 22(3): 340-342. PMID: 20653812. DOI: 10.1111/j.1540-8167.2010.01860.x.
Banavalikar B, Shenthar J, Padmanabhan D, et al. Clinical and electrophysiological correlates of incessant ivabradine-sensitive atrial tachycardia[J]. Circ Arrhythm Electrophysiol, 2019, 12(8): e007387. PMID: 31345093. DOI: 10.1161/CIRCEP.119.007387.
Tasci O, Karadeniz C. Ivabradine in a 15-day-old male neonate with refractory focal atrial tachycardia[J]. Pacing Clin Electrophysiol, 2023, 46(8): 924-927. PMID: 37428945. DOI: 10.1111/pace.14781.
Tolani D, Ramdat Misier NL, Alqahtani M, et al. Early experience with ivabradine for focal atrial tachycardia in pediatric patients with congenital heart disease[J]. Heart Rhythm, 2024, 21(1): 115-116. PMID: 37852564. DOI: 10.1016/j.hrthm.2023.10.013.
Gul O, Kafali HC, Ergul Y. Successful treatment of the focal ectopic atrial tachycardia in an infant with a single dose of ivabradin[J]. Cardiol Young, 2023, 33(9): 1750-1752. PMID: 36959114. DOI: 10.1017/S1047951123000409.
Karmegaraj B, Balaji S, Raju PN, et al. Tachycardia-induced cardiomyopathy secondary to incessant ectopic atrial tachycardia in two infants: potential new indication for early initiation of enteral ivabradine[J]. Ann Pediatr Cardiol, 2021, 14(3): 422-427. PMID: 34667421. PMCID: PMC8457284. DOI: 10.4103/apc.apc_37_21.
Dieks JK, Klehs S, Müller MJ, et al. Adjunctive ivabradine in combination with amiodarone: a novel therapy for pediatric congenital junctional ectopic tachycardia[J]. Heart Rhythm, 2016, 13(6): 1297-1302. PMID: 27216242. DOI: 10.1016/j.hrthm.2016.03.015.
Dasgupta S, Johnsrude C. Combination therapy of ivabradine with procainamide for the management of pediatric postoperative junctional ectopic tachycardia[J]. J Innov Card Rhythm Manag, 2023, 14(7): 5528-5532. PMID: 37492694. PMCID: PMC10364659. DOI: 10.19102/icrm.2023.14075.
Krishna MR, Kunde MF, Kumar RK, et al. Ivabradine in post-operative junctional ectopic tachycardia (JET): breaking new ground[J]. Pediatr Cardiol, 2019, 40(6): 1284-1288. PMID: 31317219. DOI: 10.1007/s00246-019-02149-5.
Al-Ghamdi S, Al-Fayyadh MI, Hamilton RM. Potential new indication for ivabradine: treatment of a patient with congenital junctional ectopic tachycardia[J]. J Cardiovasc Electrophysiol, 2013, 24(7): 822-824. PMID: 23373720. DOI: 10.1111/jce.12081.
Di Marco GM, De Nigris A, Pepe A, et al. Ivabradine-flecainide as breakthrough drug combination for congenital junctional ectopic tachycardia: a case report and literature review[J]. Pediatr Rep, 2021, 13(4): 624-631. PMID: 34842781. PMCID: PMC8629013. DOI: 10.3390/pediatric13040074.
Arvind B, Kothari SS, Juneja R, et al. Ivabradine versus amiodarone in the management of postoperative junctional ectopic tachycardia: a randomized, open-label, noninferiority study[J]. JACC Clin Electrophysiol, 2021, 7(8): 1052-1060. PMID: 33812837. DOI: 10.1016/j.jacep.2021.01.020.
Asfour SS, Al-Omran KA, Alodhaidan NA, et al. Ivabradine monotherapy for the treatment of congenital junctional ectopic tachycardia in a premature neonate[J]. J Pediatr Pharmacol Ther, 2021, 26(4): 414-417. PMID: 34035688. PMCID: PMC8139562. DOI: 10.5863/1551-6776-26.4.414.
Doesch AO, Mueller S, Erbel C, et al. Heart rate reduction for 36 months with ivabradine reduces left ventricular mass in cardiac allograft recipients: a long-term follow-up study[J]. Drug Des Devel Ther, 2013, 7: 1323-1328. PMID: 24235815. PMCID: PMC3821694. DOI: 10.2147/DDDT.S53705.
Rivinius R, Helmschrott M, Rahm AK, et al. Five-year results of heart rate control with ivabradine or metoprolol succinate in patients after heart transplantation[J]. Clin Res Cardiol, 2022, 111(2): 141-153. PMID: 32572551. PMCID: PMC8816306. DOI: 10.1007/s00392-020-01692-z.
Ogawa Y, Urata S, Inuzuka R. Successful use of ivabradine in a 10-year-old patient with graft failure after heart transplantation[J]. Cardiol Young, 2023, 33(4): 649-651. PMID: 35864814. DOI: 10.1017/S1047951122002335.
